Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price...

|About: NPS Pharmaceuticals, Inc. (NPSP)|By:, SA News Editor

Wedbush initiates coverage on NPS Pharmaceuticals (NPSP) at Outperform with a lofty $14 price target. Analysts with the firm expect that not only will Gattex win FDA approval, but that the cancer drug will also deliver $252M in global revenue in 2015.